Company Overview and News

58
BDX / Becton Dickinson & Co. FORM 11-K

2018-06-29 sec.gov
Form 11-K Table of Contents SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549
BDX

116
Top Analyst Upgrades and Downgrades: Charter Communications, Corning, Kohl’s, Lululemon, Nike, Verizon and More

2018-06-21 247wallst
The futures traded lower Thursday morning, and while some of the current political turmoil over immigration seems to be relieved, trade worries continue. Once again on Wednesday, the Russell 2000 index, which tracks the smaller capitalization companies, posted another record high. This streak of record highs for the index shows that many investors are moving capital to the companies that have a larger percentage of their sales and services business in the United States — a solid move if the tariff and trade war issues are prolonged.
SIRI GLW CHTR NKE BDX LULU KSS TRI PYPL

33
BDX / Becton Dickinson & Co. NYSE CERTIFICATION - BECTON DICKINSON & CO

2018-05-27 sec.gov
begin 644 BDX23A_25.8A.05.25.18.pdf M)5!$1BTQ+C,*)79E
BDX

81
BDX / Becton Dickinson & Co. FORM SD

2018-05-22 sec.gov
Form SD United States Securities and Exchange Commission Washington, D.C. 20549
BDX

51
BDX / Becton Dickinson & Co. 424B2 (Prospectus)

2018-05-21 sec.gov
TABLE OF CONTENTS
BDX

53
BDX / Becton Dickinson & Co. 424B2 (Prospectus)

2018-05-21 sec.gov
TABLE OF CONTENTS
BDX

55
BDX / Becton Dickinson & Co. FWP

2018-05-17 sec.gov
Issuer Free Writing Prospectus filed pursuant to Rule 433 Registration No. 333-224464 May 17, 2018
BDX

59
BDX / Becton Dickinson & Co. FWP

2018-05-17 sec.gov
Issuer Free Writing Prospectus filed pursuant to Rule 433 Registration No. 333-224464 May 17, 2018
BDX

42
BDX / Becton Dickinson & Co. FORM 424B2 (Prospectus)

2018-05-17 sec.gov
TABLE OF CONTENTS
BDX

48
BDX / Becton Dickinson & Co. FORM 424B2 (Prospectus)

2018-05-17 sec.gov
TABLE OF CONTENTS
BDX

33
Becton, Dickinson: More Than A Short-Term Bounce On The Cards?

2018-05-10 seekingalpha
Becton, Dickinson and Company (NYSE:BDX) printed another intra-day lower low today (9th of May) of $218.73 but rallied hard into the close to finish the trading day at $223.39. BDX's turn-around was definitely helped by the strong 20+ point rally we saw in the S&P500 (NYSE:SPX). BDX has continued its pattern of lower lows since announcing it earnings numbers last week but now because of its up-move today has strong chance of printing a daily swing low.
BDX CFN

520
Tracking William Von Mueffling's Cantillon Capital Management Portfolio - Q1 2018 Update

2018-05-09 seekingalpha
The portfolio continues to be very concentrated with the top five positions accounting for ~30% of the 13F portfolio.
FB SERV AMT.PRB AMT.PRA IBKR CMPR GOOG MHFI SPGI AMT CME AGN SSNC AVGO WSH ICE FIS BIDU CBRE TSM ECL ST EFX A BDX VRSN WLTW ZTS AON V 7018 CBG PRI GOOGL CACC ADI BITA BRCM TNET

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

46m - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2h - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

22h - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Silicon Investor Message Boards

This table lists all message boards related to BDX / Becton Dickinson & Co. on message board site Silicon Investor.

BDX: Becton, Dickinson and Co. GBDX - Global Diamond Exchange, Inc.
BDX--Becton Dickinson: finished off or opportunity knocks? BDX Becton Dickinson u0026 Company
Big Bear Exploration BDX Big Bear Acquiring Blue Range Resources
CUSIP: 075887109